ASH 2023 | Improving quality of life outcomes for patients with SCD
The quality of life (QoL) of patients with sickle cell disease (SCD) is significantly impaired on a day-to-day basis. In this video, Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, emphasizes the importance of considering QoL endpoints, such as improved pain ratings and energy levels, in clinical trials. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Agios, Novartis, BEAM Therapeutics, Forma Therapeutics, GBT/Pfizer
Advisory board: Agios, Novartis, BEAM Therapeutics, Forma Therapeutics, GBT/Pfizer
Research Funding: Novartis, Forma Therapeutics, GBT/Pfizer
Speakers Bureau: GBT/Pfizer
